Quick Facts

• FDA classified popular peptides BPC-157, CJC-1295, and Ipamorelin as Category 2 substances with safety concerns, restricting compounding pharmacy access
• Global peptide therapeutics market hit $140.86 billion in 2025 and projects to reach $294.58 billion by 2033
• FDA testing found 40% of online and compounded peptides contained incorrect dosages or undeclared ingredients

The FDA crackdown on peptide therapy has reshaped the men’s health landscape. Starting January 2025, new enforcement policies ended years of regulatory tolerance that allowed peptides to bypass traditional approval routes.

The agency classified popular peptides including BPC-157, CJC-1295, and Ipamorelin as Category 2 Bulk Drug Substances. This designation identifies significant safety risks and restricts compounding pharmacies from using these ingredients.

Dr. Elan Goldwaser, a sports medicine physician at Columbia University, said recent peptides used for anti-aging or muscle recovery remain in their “infancy” regarding research data. “While there are promising early findings, human evidence is currently very limited,” Goldwaser stated.

The regulatory shift comes as the peptide market experiences explosive growth. The global peptide therapeutics market reached $140.86 billion in 2025 and projects to hit $294.58 billion by 2033. North America holds 61.99% market share, driven by advanced research infrastructure.

Quality control remains a major concern. FDA testing revealed 40% of online and compounded peptides contained incorrect dosages or undeclared ingredients. Independent testing by Finnrick Analytics showed 78% of samples met acceptable standards with 98% purity and quantities within 20% of label claims.

Jay Campbell, author of “The Testosterone Optimization Therapy Bible,” believes regulation faces an uphill battle. “The genie is out of the bottle with peptides. We know what they can do. We know that there are millions of people in the world now using them,” Campbell said.

Men seeking peptide therapy now face stricter requirements. Pharmaceutical-grade peptides from licensed U.S. compounding pharmacies ensure sterility, potency, and regulatory compliance. Medical supervision becomes essential as improper sourcing and dosing increase risks.

Popular peptides for muscle growth include CJC-1295, Tesamorelin, IGF-1 LR3, MK-677, Sermorelin, BPC-157, and TB-500. Some peptides support testosterone by triggering gonadotropin-releasing hormone production. Kisspeptin-10 increased testosterone levels within 24 hours of injection in studies.

The FDA approved 50 novel drugs in 2024, including four peptides and oligonucleotides. Peptide and protein-based drugs now account for 25% of the global pharmaceutical market.

Dr. Liana Yates, regulatory lead at a biotechnology firm, called the changes “a course correction” rather than a simple crackdown. Men over 35 particularly benefit from peptide therapy as natural production decreases with age, affecting energy, muscle mass, and libido.

Major investments continue despite regulatory uncertainty. Novo Nordisk invested $1 billion in Brazil for GLP-1 production in April 2025. Pepticom secured $6.6 million in January 2025 for AI-powered peptide drug discovery.

Read more: The Ultimate Men’s Health Guide to Peptides